Variable | Non-MDR-TB n=48 | MDR-TB n=245 | Total | p Value |
---|---|---|---|---|
Supervised treatment (DOT) | <0.0001* | |||
Unsupervised treatment | 28 (58.3%) | 53 (21.6%) | 81 (27.6%) | |
Supervised treatment | 20 (41.7%) | 192 (78.4%) | 212 (72.4%) | |
Type of DOT provider | 0.36* | |||
Trained provider† | 16 (80%) | 135 (70.3%) | 151 (71.2%) | |
Family/other provider‡ | 4 (20%) | 57 (29.7%) | 61 (28.8%) | |
Type of treatment unit | <0.0001* | |||
Private centre | 14 (29.2%) | 10 (4.1%) | 24 (8.2%) | |
Designated DOTS centre | 34 (70.8%) | 235 (95.9%) | 269 (91.8%) | |
Follow-up by the providers after incomplete treatment | <0.0001* | |||
No follow-up | 12 (85.7%) | 13 (8.4%) | 25 (14.8%) | |
Follow-up done | 2 (14.3%) | 142 (91.6%) | 144 (85.2%) | |
Time-to-treatment centre (min) | 0.0005§ | |||
Mean | 49.8 | 29.7 | 32.9 | |
Median | 40 | 20 | 30 | |
SD | 34.7 | 35.5 | 36.1 | |
Range | 5–150 | 1–420 | 1–420 | |
Cost-to-treatment centre (BDT) | 0.46§ | |||
Mean | 27.3 | 22.9 | 23.6 | |
Median | 20 | 15 | 20 | |
SD | 22 | 38.3 | 36.1 | |
Range | 0–100 | 0–500 | 0–500 | |
Distance-to-treatment centre (miles) | 0.91§ | |||
Mean | 4.6 | 4.3 | 4.3 | |
Median | 3 | 2 | 2 | |
SD | 4 | 16.1 | 14.9 | |
Range | 0.2–15 | 0–175 | 0–175 |
US$1 is 77 BDT approximately.
Time-to-treatment, cost-to-treatment and distance-to-treatment centres had a total of 286, 283 and 285 observations, respectively.
*Probability of χ2 test.
†Trained providers include providers trained on supervision on medicine intake (DOT) such as community health volunteers, health workers at facility and field level and village doctors.
‡‘Family and other providers’ include family members, neighbours and other volunteers supervising the treatment.
§Probability of Student t-test.
BDT, Bangladesh taka; DOT, directly observed treatment; DOTS, DOT, short-course; MDR-TB, multidrug-resistant tuberculosis.